MedTrace Logo

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

NCT06758700 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-12-05

No results posted yet for this study

Summary

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Conditions

  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)
  • Thoracic Neoplasms
  • Lung Neoplasms
  • Lung Diseases

Interventions

DRUG

Teniposide administration

Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 3-5 consecutive days, with 21 days as one cycle of treatment.

Sponsors & Collaborators

  • CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD

    collaborator UNKNOWN

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-07
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06758700 on ClinicalTrials.gov